SPATA2 Double Nickase Plasmid (h): sc-406210-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SPATA2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- SPATA2 Double Nickase Plasmid (h) and SPATA2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting SPATA2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SPATA2 Antibody (B-7): sc-515283
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SPATA2 Double Nickase Plasmid (h) | sc-406210-NIC | 20 µg | $410.00 | |||
SPATA2 Double Nickase Plasmid (h2) | sc-406210-NIC-2 | 20 µg | $410.00 |
SPATA2 (spermatogenesis-associated protein 2) encodes an adaptor protein implicated in ubiquitin-dependent signaling and stress-responsive pathways. SPATA2 has been reported to interact with components of the linear ubiquitin chain assembly complex (LUBAC) and related regulators, influencing NF-κB pathway dynamics, inflammatory signaling, and cell survival decisions. Through these interactions, SPATA2 is studied in the context of proteostasis, apoptosis/necrosis balance, and innate immune pathway tuning. Altered regulation of these processes has relevance to cancer biology and inflammatory disease mechanisms, supporting its use as a target in pathway dissection studies.
SPATA2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the SPATA2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within SPATA2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt SPATA2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of SPATA2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.